On March 10, 2011, King Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc., voluntarily recalled all dosage forms of Embeda® (morphine and naltrexone) extended release capsules from U.S. wholesalers and retailers. According to King, a pre-specified stability requirement was not met during routine testing.
Based on available data, King says that Embeda is unlikely to cause adverse health consequences to patients using it as prescribed by their physicians. If you are currently taking Embeda,...
